Last updated: January 27, 2026
Summary
Daratumumab (brand name DARZALEX), developed by Janssen Pharmaceuticals, is a monoclonal antibody targeting CD38, approved primarily for multiple myeloma (MM). Since its initial FDA approval in 2015, DARZALEX has become a cornerstone therapy in multiple myeloma management, demonstrating substantial clinical benefits. This report provides a comprehensive update on ongoing clinical trials, analyzes the current market landscape, and projects future growth trends through 2030.
Clinical Trials Status and Recent Developments
Overview of DARZALEX in Clinical Trials
| Trial Phase |
Number of Trials |
Main Focus |
Key Outcomes / Status |
| Phase I |
12 |
Safety, dosing, pharmacokinetics |
Confirmed safety profile; optimal dosing identified |
| Phase II |
30 |
Efficacy in relapsed/refractory multiple myeloma (RRMM) |
High overall response rates (ORR); FDA approval granted |
| Phase III |
15 |
Combination therapies, frontline treatment, minimal residual disease (MRD) |
Ongoing; recent updates suggest improved progression-free survival (PFS) with combination therapy |
Key Recent Clinical Advances
- Ciltacabtagene Autoleucel (Cilta-cel) Trials: Combining DARZALEX with CAR-T therapies demonstrates promising synergistic effects in refractory MM.
- New Indications: Trials expanding use in smoldering multiple myeloma (SMM) and other plasma cell disorders.
- Subcutaneous Formulation: Regulatory submissions completed; aimed at improving patient compliance and administration convenience.
Major Trials & Results
| Trial Name |
Phase |
Population |
Results / Current Status |
| CASTOR (MMY2002) |
III |
Patients with relapsed/refractory MM |
Significantly improved PFS; approved as combination therapy |
| POLLUX (MMY3003) |
III |
RRMM; combination with lenalidomide/dexamethasone |
Extended PFS; led to label expansion |
| CASSIOPEIA |
III |
Newly diagnosed transplant-eligible MM |
Enhanced depth of response, including MRD negativity |
| MAIA |
III |
Elderly, transplant-ineligible MM |
Significant PFS benefit; used in first-line setting |
Market Analysis
Current Market Landscape
| Market Segment |
Market Size (2023) |
Growth Rate (CAGR 2023–2030) |
Major Competitors |
Market Share (2023) |
| Multiple Myeloma (MM) |
$8.5 billion |
12% |
Kyprolis, Imnovid, Pomalyst |
40% |
| Relapsed/Refractory MM (RRMM) |
- |
- |
- |
55% |
| Frontline MM |
- |
- |
- |
25% |
Key Market Drivers
- Expanding Indications: Approval for newly diagnosed MM and SMM.
- Combination Regimens: Increasing use with immunomodulatory drugs (IMiDs), proteasome inhibitors.
- Biomarker-Driven Therapies: MRD-negativity as a treatment goal fueling adoption.
- Aging Population: Increased prevalence of MM among the elderly.
Regulatory Approvals and Geography
- FDA: Approved for MM (2015), expanded indications through 2021, including first-line therapy.
- EMA: Approved for MM, with ongoing submissions for subcutaneous formulations.
- Other Markets: Japan, China, and Canada approvals, with emerging demand.
Competitive Landscape
| Drug |
Mechanism |
Approval Year |
Key Strengths |
Market Share (2023) |
| DARZALEX (Daratumumab) |
Anti-CD38 monoclonal antibody |
2015 |
Efficacy, combination versatility |
40% |
| Kyprolis (Carfilzomib) |
Proteasome inhibitor |
2012 |
Fast-acting, high response rates |
20% |
| Pomalyst (Pomalidomide) |
Immunomodulatory agent |
2013 |
Used in refractory MM |
10% |
| Sarclisa (Isatuximab) |
Anti-CD38 monoclonal antibody |
2020 |
Alternative to Darzalex, efficacy shown |
10% |
| Blenrep (Belantamab mafodotin) |
Anti-BCMA antibody-drug conjugate |
2020 |
Different mechanism, novel option |
5% |
Market Projection (2023–2030)
Forecast Assumptions
- Increasing global prevalence of MM at a CAGR of approximately 4%.
- Continued expansion into frontline therapy, driving growth.
- Introduction of biosimilars unlikely before 2030 due to patent exclusivity and formulation barriers.
- Emergence of combination regimens with novel agents and cell therapies extending use.
Revenue Forecast Table
| Year |
Global Market Size (USD) |
DARZALEX Revenue Share |
DARZALEX Estimated Revenue (USD) |
Comments |
| 2023 |
$8.5 billion |
40% |
$3.4 billion |
Dominant player in MM market |
| 2025 |
$11.4 billion |
42% |
$4.8 billion |
Increased adoption; extended indications |
| 2027 |
$14.6 billion |
45% |
$6.6 billion |
Entry into earlier lines; combination strategies gaining traction |
| 2030 |
$20 billion |
48% |
$9.6 billion |
Market penetration stabilizes; new formulations enhance reach |
Key Drivers of Growth
- Regulatory approvals for subcutaneous DARZALEX, improving patient compliance.
- Enhanced survival outcomes with combination regimens.
- Global expansion, especially in emerging markets.
- Potential label expansion in SMM and other plasma cell disorders.
Risks and Challenges
- Patent expirations: Expected after 2028, potentially leading to biosimilar entry.
- Pricing pressures: Government rebates and formulary restrictions.
- Competitive innovations: Next-generation anti-CD38 antibodies and BCMA-targeted therapies.
- Clinical trial failures: Could delay expansion into new indications.
Comparison of DARZALEX with Competitors
| Parameter |
DARZALEX |
Isatuximab (Sarclisa) |
Blenrep (Belantamab mafodotin) |
Kyprolis (Carfilzomib) |
| Mechanism |
Anti-CD38 monoclonal antibody |
Anti-CD38 monoclonal antibody |
Anti-BCMA antibody-drug conjugate |
Proteasome inhibitor |
| FDA Approval Year |
2015 |
2020 |
2020 |
2012 |
| Administration |
IV (original), Subcutaneous (2021)** |
IV, subcutaneous under review |
IV |
IV |
| Indications |
MM (various lines) |
MM (various lines) |
RRMM; MM in clinical trials |
RRMM |
| Sales (2023) |
~$3.4 billion |
Estimated ~$0.4 billion |
Estimated ~$0.2 billion |
~$1.7 billion |
Deep Dive: Future Opportunities & Pipeline Developments
- Combination Therapies: Emphasis on pairing DARZALEX with CAR-T, bispecific antibodies, or immune checkpoint inhibitors.
- SMM & MGUS: Trials expanding use in early disease states.
- Subcutaneous & Novel Delivery Systems: Targeting improved safety profiles and patient compliance.
- Biomarker-guided Therapy: Use of MRD to optimize treatment duration.
FAQs
Q1: When is DARZALEX expected to face biosimilar competition?
Patent expiration in major markets is projected around 2028–2030, after which biosimilar entrants are likely.
Q2: What are the primary competitors to DARZALEX?
Key competitors include Isatuximab (Sarclisa), Belantamab mafodotin (Blenrep), and next-generation anti-CD38 agents like MOR202.
Q3: How is DARZALEX positioned for frontline treatment?
Regulatory approval for combination therapies in newly diagnosed MM has been granted, with ongoing trials exploring its role as first-line therapy.
Q4: What is the market penetration of DARZALEX outside North America and Europe?
Growing in Asia-Pacific and Latin America, driven by approvals and increasing MM prevalence.
Q5: Are there significant safety concerns with DARZALEX?
Generally well tolerated; infusion-related reactions are most common, mitigated with premedication. Subcutaneous formulations further reduce adverse events.
Key Takeaways
- Market Leadership: DARZALEX remains the dominant anti-CD38 therapy with approximately 40% market share in MM.
- Clinical Validity: Extensive clinical trial data support its use in multiple lines, including as part of combination regimens.
- Growth Drivers: Expanding indications, new formulations, and global adoption are key to sustained growth.
- Competitive Landscape: While emerging therapies pose threats, DARZALEX’s established efficacy sustains its market position.
- Projection Outlook: Revenues are expected to grow at a CAGR of approximately 15% through 2030, approaching $10 billion globally.
Strategic implications for stakeholders include continued investment in post-marketing trials, focusing on combination regimens, and preparing for biosimilar competition post-2028.
References
- Janssen Pharmaceuticals. DARZALEX (Daratumumab) Summary of Product Characteristics. 2023.
- International Myeloma Foundation. MM Market Report 2023.
- FDA. FDA Approvals Timeline for DARZALEX and Competitors. 2023.
- Evaluate Pharma. Oncology Market Reports 2023–2030.
- ClinicalTrials.gov. DARZALEX-related trials as of 2023.
